Biolight Life Sciences Ltd. · TASE:BOLT
Biolight Life Sciences — Investor Presentation (September 2025)
15 slides from Biolight Life Sciences's investor presentation, Sep 8, 2025
Slide 1: A Glimpse into the Future
A Glimpse into the Future * This is a translated version of Company’s corporate presentation in Hebrew as filed with the Israeli TASE on September 8, 2025 - created for convenience purposes only. Building on Past Experience to Create Current Value and Promote the Companies of the Future
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation has been prepared by Biolight Life Sciences Ltd. ("Biolight") and contains summary information only. It is solely intended to provide general information regarding Biolight’s activities, its subsidiaries and affiliated companies (collectively named "The Co
Slide 3: Portfolio Valuation Potential
Portfolio Valuation Potential * Building on Past Experience to Create Current value and Promote the Companies of the Future NIS Million * Based on the assumptions and comparable companies, as specified, for each portfolio company, further along this presentation and subject to the realization of the
Slide 4: Building on Past Experience to Create Current Value
Building on Past Experience to Create Current Value and Promote the Companies of the Future
Slide 5: Creating Value Today: 12–24 Months
Creating Value Today 12–24 Months Holding Valuation Potential Holding Valuation Potential 5% 62 million NIS 46% 85 million NIS Holding Value Potential Holding Valuation Potential 39% 56 million NIS ~ *83% 184 million NIS * A planned merger between OphRx (58%) and ViSci (88%) is underway. The final a
Slide 6: Drug delivery platform for the eye's anterior segment and retina
A platform providing a comprehensive solution for drug delivery to the eye’s anterior segment and retina OphRx’s Technology ViSci Biodegradable implant • Enables delivery of drugs to the back of the eye • Enables sustained drug release via eye drops • The non-biodegradable conjunctival implant • Saf
Slide 7: TeaRx: diagnosing anterior segment eye diseases using tear analysis
Technology - Designed for diagnosing anterior segment eye diseases using tear analysis TeaRx Dry Eye Red Eye Diagnostic product for dry eye Diagnostic product for red eye diagnosis diagnosis (Received CE Mark and (Currently in a human feasibility study in AMAR approval) Israel) For the differential
Slide 8: Developing an Innovative Drug for Uveitis
Developing an Innovative Drug for Uveitis • A unique mechanism of action that activates the immune system towards an anti-inflammatory response • An innovative, patent-protected drug designed to treat non-infectious ocular inflammation without the vision- threatening side effects of steroids, which
Slide 9: Technology platform for testing peripheral vision impairment
Innovative technology platform for testing peripheral vision impairment • Enables an objective and easy-to-perform evaluation of peripheral vision, using a laptop • Can be conducted by the patient at home or at the clinic setting • Much simpler and faster than tests currently performed with the equi
Slide 10: Planned Future Investments
Creating Creating Value in the present and in the future Planned Future Investments 3-5 1 1 million $ million $ million $ Completion of Phase II Commercial launch Developing a diagnostic kit for AMD, in one of the products in the U.S> following the positive results of the clinical trial in humans th
Slide 11: Detailed Valuation Potential
Detailed Valuation Potential Basis for Valuation Scenario Valuation Potential of Biolight’s Stake Description of its Operations Company Name Engaged in drug delivery to the retina Upon an IPO or strategic transaction Pre-money valuation in the August 2025 via eye drops and sustained release in NIS 1
Slide 12: Management Team
Management Team A highly experienced and knowledgeable leadership team with a proven track record Yifftach Biel Yaacov Michlin Israel Makov CFO CEO Chairman of the Board Formerly: CEO of Teva, Chairman of Sun Pharmaceutical Industries, and more Scientific Advisory Board for Biolight / Key Portfolio
Slide 13: Holdings' Chart
Holdings’ Chart Subsidiaries - Build to Partner Affiliated Company * ~83% 46% 38% Exits & Royalty Transactions Held Companies - VC approach 92% 4% 5% 5% 8% Phase III CE Approval As of 30 June 2025 * A planned merger between OphRx (58%) and ViSci (88%) is underway. The final and exact holding percent
Slide 14: Seven Balls in the Air
Seven Balls in the Air The Company has resolved to pursue a policy whereby it shall consider distributing dividends to its shareholders in an amount equal to 50% of the "Net Cash Amount" actually obtained from the realization of its holdings in portfolio companies (after offsetting the original inve
Slide 15: Thank You
Thank You Yaacov@bio-light.co.il | http://bio-light.co.il בונים על ניסיון העבר כדי ליצור ערך בהווה ולהרים את חברות העתיד
Biolight Life Sciences — Investor Presentation (September 2025) on 6ix